United States-based Gilead Sciences Inc (Nasdaq: GILD) has collaborated with the Renown Institute for Health Innovation.
It was reported on Friday that the collaboration is aimed at collecting and analysing genetic and electronic health data that can improve the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. According to the terms of the collaboration and license agreement, Gilead will provide funding to Renown Institute for Health Innovation to sequence and analyse the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) and a control cohort of 40,000 individuals in Nevada.
John McHutchison, AO, MD, chief scientific officer and head of Research and Development, Gilead Sciences, said, 'Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression. The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.'
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002